histidine has been researched along with B-Cell Chronic Lymphocytic Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brancaccio, M; Castellano, I; Masullo, M; Palumbo, A; Russo, GL; Russo, M | 1 |
| Chen, T; Chorev, M; Ge, X; Huang, Y; Liu, F; Liu, H; Qin, X; Su, S; Sun, X; Wang, C; Wang, X; Wu, L; Xu, T | 1 |
2 other study(ies) available for histidine and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Sulfur-containing histidine compounds inhibit γ-glutamyl transpeptidase activity in human cancer cells.
Topics: Autophagy; Cell Line, Tumor; Cell Proliferation; gamma-Glutamyltransferase; Gene Expression Regulation, Neoplastic; Glutathione; Histidine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Methylhistidines; Oxidation-Reduction; Proteolysis; Substrate Specificity; Sulfur Compounds | 2019 |
Removal of the tag from His-tagged ILYd4, a human CD59 inhibitor, significantly improves its physical properties and its activity.
Topics: Amino Acid Sequence; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bacteriocins; CD59 Antigens; Chemotherapy, Adjuvant; Drug Design; Drug Resistance, Neoplasm; Drug Stability; Histidine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Rituximab; Solubility | 2012 |